US 12,478,613 B2
Selective MAO-B inhibitor DRG-MAOB-2 for use in treatment of neurodegenerative diseases
Serdar Durdagi, Besiktas/Istanbul (TR); Mine Yurtsever, Besiktas/Istanbul (TR); Yusuf Serhat Is, Besiktas/Istanbul (TR); Busecan Aksoydan, Besiktas/Istanbul (TR); and Murat Senturk, Besiktas/Istanbul (TR)
Assigned to BAHCESEHIR UNIVERSITESI, Istanbul (TR); AGRI IBRAHIM CECEN UNIVERSITESI STRATEJI DAIRE BASK., Istanbul (TR); ISTANBUL GEDIK UNIVERSITESI, Istanbul (TR); and ISTANBUL TEKNIK UNIVERSITESI REKTORLUGU, Istanbul (TR)
Appl. No. 17/904,997
Filed by BAHCESEHIR UNIVERSITESI, Besiktas/Instanbul (TR); AGRI IBRAHIM CECEN UNIVERSITESI STRATEJI DAIRE BASK., Agri (TR); ISTANBUL GEDIK UNIVERSITESI, Istanbul (TR); and ISTANBUL TEKNIK UNIVERSITESI REKTORLUGU, Istanbul (TR)
PCT Filed Feb. 25, 2021, PCT No. PCT/TR2021/050171
§ 371(c)(1), (2) Date Aug. 25, 2022,
PCT Pub. No. WO2021/173103, PCT Pub. Date Sep. 2, 2021.
Claims priority of application No. 2020/02935 (TR), filed on Feb. 26, 2020.
Prior Publication US 2023/0088611 A1, Mar. 23, 2023
Int. Cl. A61K 31/4184 (2006.01); A61K 45/06 (2006.01); C07D 403/12 (2006.01)
CPC A61K 31/4184 (2013.01) [A61K 45/06 (2013.01); C07D 403/12 (2013.01)] 4 Claims
 
1. A pharmaceutical composition comprising a compound of Formula I,

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable derivative thereof, and at least one pharmaceutically acceptable excipient.